Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1800/000104746909001642/a2188623z10-k.htm
Exhibit 99.1 |
|||||
|
|||||
|
Abbott Reports Double-Digit Sales and Earnings
Growth in |
||||
|
|
|
|
|
|
|
Worldwide Sales Increased 10.1 Percent |
||||
|
Adjusted EPS Growth of 14.0 Percent (GAAP EPS up 27.3 Percent) |
||||
|
Delivers Double-Digit Sales Growth in Each Major Global Business in 2008 |
||||
|
Concludes Successful 2008 with Nine New Major Regulatory Approvals |
||||
|
Confirms Double-Digit Earnings-Per-Share Growth in 2009 |
||||
|
|
|
|
|
|
|
ABBOTT PARK, III., Jan. 21, 2009 Abbott today announced financial results for the fourth quarter |
||||
Financial: |
ended Dec. 31, 2008. |
||||
John Thomas |
|
|
|
||
(847) 938-2655
Larry Peepo |
· |
Diluted earnings per share, excluding specified items, were $1.06, reflecting 14.0 percent growth, in line with Abbotts previous forecast. Diluted earnings per share under Generally Accepted Accounting Principles (GAAP) were $0.98, up 27.3 percent. |
|||
(847) 935-6722 |
|
|
|||
|
· |
Worldwide sales increased 10.1 percent to $8 billion, including an unfavorable 2.5 percent effect of exchange rates. Full-year 2008 sales were nearly $30 billion. |
|||
Tina Ventura |
|
||||
(847) 935-9390 |
|
|
|||
|
· |
Worldwide pharmaceutical sales increased nearly 10 percent driven by double-digit growth in HUMIRA®, Niaspan®, and the TriCor®/TRILIPIX franchise. Global HUMIRA sales in the quarter exceeded $1.3 billion; full-year 2008 global HUMIRA sales were more than $4.5 billion. |
|||
Media: |
|
||||
Melissa Brotz |
|
||||
(847) 935-3456 |
|
|
|||
|
· |
Worldwide medical products sales increased 15.6 percent; with 58.9 percent growth in global vascular sales driven by the continued success of the XIENCE V drug-eluting stent (DES), which became the market-leading DES in the U.S. during the fourth quarter. Last week, Abbott announced the acquisition of Advanced Medical Optics (AMO), strengthening and expanding Abbotts medical device business with a global market leader in ophthalmology. |
|||
Scott Stoffel |
|
||||
(847) 936-9502 |
|
||||
|
|
||||
|
|
||||
|
|
|
|||
|
· |
Global nutritional sales increased 11.0 percent, up more than 15 percent internationally and nearly 7 percent in the U.S. |
|||
|
|
||||
|
|
|
|||
|
· |
Abbott is confirming previously issued earnings-per-share guidance for the full-year 2009 of $3.65 to $3.70 under both Generally Accepted Accounting Principles (GAAP) and on a non-GAAP basis. The midpoint of this 2009 guidance range reflects double-digit growth over 2008 earnings per share. |
|||
|
|
|
|||
|
2008 was another highly productive and successful year for Abbott, said Miles D. White, chairman and chief executive officer, Abbott. We significantly outperformed our original growth expectations for the year and added to our diverse portfolio with a significant number of major new product launches. The strategic actions weve taken and our ongoing business momentum position Abbott to deliver continued double-digit growth in 2009. |
||||
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Abbott Laboratories.
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1800/000104746909001642/a2188623z10-k.htm
Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.
ContinueRead positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.
ContinueRemove data columns and navigations in order to see much more filing content and tables in one view
ContinueRead both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q
ContinueExport Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis
ContinueGet one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports
Continue for FREEOur Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not
ContinueOur Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity
ContinueSee how over 70
Growth, Profitability and Financial Ratios perform over 10 Years